Navigation Links
AHF Challenges Merck Over Steep Price of Its New AIDS Drug, Isentress
Date:10/15/2007

Company Prices New HIV/AIDS Salvage Drug at $9,900 USD Per Patient Yearly Following FDA's Recent Approval of Isentress, Merck's New Integrase Inhibitor. AHF Decries Overall Price Spiral on New AIDS Drugs; Urges Restraint by Entire Pharmaceutical Industry in Pricing

LOS ANGELES, Oct. 15 /PRNewswire-USNewswire/ -- AIDS Healthcare Foundation (AHF) today criticized Merck and Co. Pharmaceuticals, for the announced price for its key new HIV/AIDS drug, Isentress (raltegravir), an integrase inhibitor approved by the Food and Drug Administration (FDA) Friday, and priced by the company at nearly $9,900 per patient yearly. Today's Kaiser Daily HIV/AIDS Report noted that Isentress is an integrase inhibitor that "...decreases HIV viral loads after 24 weeks of use among HIV-positive people who have not responded to other treatments," according to a study published in the April 14 online edition of the journal Lancet."

"We commend Merck for the development of this new HIV/AIDS drug that shows particular promise as a salvage therapy, but urge the company to reconsider its action and set the price of this lifesaving medicine so it is affordable," said Michael Weinstein, AIDS Healthcare Foundation President. "The steep cost of this new drug is symptomatic of the overall price spiral of AIDS drugs. As with many other AIDS drugs before it, the price is simply out of reach for most AIDS patients, and Merck and other companies' pricing for their AIDS drugs threatens to further limit the ability of Medicaid and AIDS Drug Assistance Programs nationwide to provide crucial medications to its patient populations."

According to a Reuters news article, "The company (Merck) said it would charge about $27 per day, or $9,855 annually, for the drug. Steep prices for AIDS drugs have been criticized by patients and advocacy groups, who say they deter use of lifesaving drugs."

In 2004, Roche & Trimeris created an international uproar when its drug Fuzeon, also widely used as a second or third-line salvage therapy, was first introduced and priced at $20,000 USD per year, per patient--far above what analysts had expected.

AHF's Weinstein added, "AIDS drugs are priced at the maximum the market will bear, regardless of production costs. Other drug makers continue to follow suit with equally high prices, and access to care and treatment is the casualty. We challenge both Merck and the pharmaceutical industry as a whole to set pricing and access policies for these potentially lifesaving AIDS drugs in a manner that illustrates its concern for patient quality of life, rather than contributing to the public's growing crisis of confidence in it."

About AHF

AIDS Healthcare Foundation (AHF) is the US' largest non-profit HIV/AIDS healthcare, research, prevention and education provider. AHF currently provides medical care and/or services to more than 61,000 individuals in 15 countries worldwide in the US, Africa, Latin America/Caribbean and Asia. Additional information is available at http://www.aidshealth.org


'/>"/>
SOURCE AIDS Healthcare Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Momentum of Stem cell research impeded by legal challenges
2. Australia Ready to Meet the Challenges of Bird Flu
3. Sexual Health Service Is Under Pressure and Faced With Financial Challenges
4. Abuja Challenges the Government
5. Nurses in South Africa Face Challenges
6. Bangladesh Progressing But Must Yet Face Challenges In Health Sector
7. Fresh Water, HIV Biggest of Indias Six Challenges: Chidambaram
8. New Study Challenges How Regulators Determine Risk
9. FDA Cites Challenges of Generic Biotech
10. Study Challenges Conventional Treatment of Traumatic Brain Injury
11. Challenges in Entecavir Drug Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology: